Cost Effectiveness of PrEP Intervention

The World Health Organization (WHO) recommends pre-exposure prophylaxis (PrEP) among the population at substantially HIV risk. Despite many randomized controlled trials illustrating efficacy of the intervention, and many intervention being carried out, only few countries have embraced PrEp as a preventative care (WHO, 2012). WHO has released many position statements recommending PrEP among people at high risk of contracting HIV. The daily use of oral Truvada among HIV negative people was approved in the USA in 2012 (WHO, 2012). However, many countries including Australia and Europe have not allowed PrEP intervention. Modelling studies are believed to be the best approach in unearthing the long-term impact of PrEP intervention among different population groups (WHO 2012). Scholars have heavily documented the cost of introducing PrEP and its cost effectiveness in various countries. Despite its slow uptake in many countries, PrEP is a cost effective intervention against HIV.

R...